Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-BCGvacc: predicting BCG vaccine response from pre-vaccination immune status
NL-OMON59010Phase 4Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bacillus calmette-guerin substrain danish 1331 live antigen in Tuberculosis (TB), sponsored by Leiden University Medical Center. Primary endpoint: In vitro mycobacterial growth control by MGIA. Started Oct 2025; status: recruiting.
02
Drugs
bacillus calmette-guerin substrain danish 1331 live antigen
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NL-OMON59010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59010.